Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.